160 related articles for article (PubMed ID: 19906270)
41. An association between type 1 diabetes and idiopathic generalized epilepsy.
Vulliemoz S; Seeck M
Ann Neurol; 2006 Apr; 59(4):728. PubMed ID: 16566023
[No Abstract] [Full Text] [Related]
42. Intravenous immunoglobulin and rituximab for cerebellar ataxia with glutamic acid decarboxylase autoantibodies.
Planche V; Marques A; Ulla M; Ruivard M; Durif F
Cerebellum; 2014 Jun; 13(3):318-22. PubMed ID: 24218114
[TBL] [Abstract][Full Text] [Related]
43. Membranous nephropathy and cerebellar degeneration with anti-GAD antibodies in type 2 diabetes mellitus.
Folli F; Daniele G; Werner S; Kamath S; Munera JV; Abboud H; Fanti P
Acta Diabetol; 2015 Oct; 52(5):897-903. PubMed ID: 25753172
[TBL] [Abstract][Full Text] [Related]
44. [Cytoplasmic islet cell antibodies and GAD antibodies in diagnosis of diabetes].
Bieg S; Seissler J; Scherbaum WA
Med Klin (Munich); 1995 Oct; 90(10):594-8. PubMed ID: 7500923
[No Abstract] [Full Text] [Related]
45. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor.
Sillevis Smitt P; Kinoshita A; De Leeuw B; Moll W; Coesmans M; Jaarsma D; Henzen-Logmans S; Vecht C; De Zeeuw C; Sekiyama N; Nakanishi S; Shigemoto R
N Engl J Med; 2000 Jan; 342(1):21-7. PubMed ID: 10620645
[No Abstract] [Full Text] [Related]
46. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus.
Solimena M; Folli F; Denis-Donini S; Comi GC; Pozza G; De Camilli P; Vicari AM
N Engl J Med; 1988 Apr; 318(16):1012-20. PubMed ID: 3281011
[TBL] [Abstract][Full Text] [Related]
47. Progressive hearing loss and cerebellar ataxia in anti-Ma2-associated autoimmune encephalitis.
Souza PV; Bortholin T; Pinto WB; Santos AJ
Arq Neuropsiquiatr; 2017 Jan; 75(1):74-75. PubMed ID: 28099568
[No Abstract] [Full Text] [Related]
48. High Titer of Circulating Antiglutamic Acid Decarboxylase Antibodies in a Patient with Cerebellar Ataxia and Type 1 Diabetes.
Kataria R; Fernandes S; Lebastchi J; Bravo CA; Sena KN
Conn Med; 2017 Mar; 81(3):161-164. PubMed ID: 29772159
[TBL] [Abstract][Full Text] [Related]
49. Anti-glutamic acid decarboxylase limbic encephalitis without epilepsy evolving into dementia with cerebellar ataxia.
Mirabelli-Badenier M; Morana G; Pinto F; Uccelli A; Veneselli E; Battaglia FM; Biancheri R; Baglietto MG; Vincent A; Mancardi MM
Arch Neurol; 2012 Aug; 69(8):1064-6. PubMed ID: 22507885
[TBL] [Abstract][Full Text] [Related]
50. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia.
Takenoshita H; Shizuka-Ikeda M; Mitoma H; Song S; Harigaya Y; Igeta Y; Yaguchi M; Ishida K; Shoji M; Tanaka M; Mizusawa H; Okamoto K
J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):386-9. PubMed ID: 11181864
[TBL] [Abstract][Full Text] [Related]
51. [Vaccine for prevention of type 1 diabetes mellitus].
Surković I; Suljević I; Ascić-Buturović B; Heljić B
Med Arh; 2006; 60(3):198-9. PubMed ID: 16719238
[TBL] [Abstract][Full Text] [Related]
52. Autoantibodies associated with presymptomatic insulin-dependent diabetes mellitus in women.
Whittingham S; Byron SL; Tuomilehto J; Zimmet PZ; Myers MA; Vidgren G; Rowley MJ; Feeney SJ; Koskela P; Tuomilehto-Wolf E; Mackay IR
Diabet Med; 1997 Aug; 14(8):678-85. PubMed ID: 9272595
[TBL] [Abstract][Full Text] [Related]
53. Response to steroid treatment in anti-glutamic acid decarboxylase antibody-associated cerebellar ataxia, stiff person syndrome and polyendocrinopathy.
Kim JY; Chung EJ; Kim JH; Jung KY; Lee WY
Mov Disord; 2006 Dec; 21(12):2263-4. PubMed ID: 17013903
[No Abstract] [Full Text] [Related]
54. Anti glutamate-decarboxylase antibodies: a liaison between localisation related epilepsy, stiff-person syndrome and type-1 diabetes mellitus.
Szűcs A; Barcs G; Winkler G; Soós Z; Folyovich A; Kelemen A; Várallyay P; Kamondi A
Ideggyogy Sz; 2014 Jul; 67(7-8):269-71. PubMed ID: 25509368
[TBL] [Abstract][Full Text] [Related]
55. Autoantibodies to GAD and IA-2 in Saudi Arabian diabetic patients.
Damanhouri LH; Dromey JA; Christie MR; Nasrat HA; Ardawi MS; Robins RA; Todd I
Diabet Med; 2005 Apr; 22(4):448-52. PubMed ID: 15787671
[TBL] [Abstract][Full Text] [Related]
56. Persistent GAD 65 antibodies in longstanding IDDM are not associated with residual beta-cell function, neuropathy or HLA-DR status.
Jaeger C; Allendörfer J; Hatziagelaki E; Dyrberg T; Bergis KH; Federlin K; Bretzel RG
Horm Metab Res; 1997 Oct; 29(10):510-5. PubMed ID: 9405979
[TBL] [Abstract][Full Text] [Related]
57. [Autoantibodies in type 1 diabetes mellitus].
Ziegler M; Ziegler B
Z Arztl Fortbild (Jena); 1994 Aug; 88(7-8):561-5. PubMed ID: 7856261
[No Abstract] [Full Text] [Related]
58. GAD-65 autoantibody associated epilepsy.
Dimova R; Grozeva G; Chakarova N; Tsarkova P; Tankova T
J Pediatr Endocrinol Metab; 2020 May; 33(6):817-820. PubMed ID: 32436860
[TBL] [Abstract][Full Text] [Related]
59. Prevalence of Autoantibodies and the Efficacy of Immunotherapy for Autoimmune Cerebellar Ataxia.
Nanri K; Okuma M; Sato S; Yoneda M; Taguchi T; Mitoma H; Yamada J; Unezaki S; Nagatani T; Otsubo S; Sugawara M; Tanaka N; Mizusawa H
Intern Med; 2016; 55(5):449-54. PubMed ID: 26935362
[TBL] [Abstract][Full Text] [Related]
60. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA).
Lohmann T; Kellner K; Verlohren HJ; Krug J; Steindorf J; Scherbaum WA; Seissler J
Diabetologia; 2001 Aug; 44(8):1005-10. PubMed ID: 11484077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
